» Articles » PMID: 30729704

Chondroprotection of PPARα Activation by WY14643 Via Autophagy Involving Akt and ERK in LPS-treated Mouse Chondrocytes and Osteoarthritis Model

Overview
Journal J Cell Mol Med
Date 2019 Feb 8
PMID 30729704
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Autophagy maintains cellular homoeostasis. The enhancement of autophagy in chondrocytes could prevent osteoarthritis (OA) progression in articular cartilage. Peroxisome proliferator-activated receptor α (PPARα) activation may also protect articular chondrocytes against cartilage degradation in OA. However, whether the protective effect of activated PPARα is associated with autophagy induction in chondrocytes is not determined. In this study, we investigated the effect of PPARα activation by its agonist, WY14643, on the protein expression level of Aggrecan and ADAMTS5, and the protein expression level of autophagy biomarkers, including LC3B and P62, using Western blotting analysis in isolated mouse chondrocytes pre-treated with lipopolysaccharides (LPS, mimicking OA chondrocytes) with or without the autophagy inhibitor chloroquine diphosphate salt. Furthermore, Akt and ERK phosphorylation was detected in LPS-treated chondrocytes in response to WY14643. In addition, the effect of intra-articularly injected WY14643 on articular cartilage in a mouse OA model established by the destabilization of the medial meniscus was assessed using the Osteoarthritis Research Society International (OARSI) histopathology assessment system, along with the detection of Aggrecan, ADAMTS5, LC3B and P62 protein levels using immunohistochemistry assay. The results indicated that PPARα activation by WY14643 promoted proteoglycan synthesis by autophagy enhancement in OA chondrocytes in vivo and in vitro concomitant with the elevation of Akt and ERK phosphorylation. Therefore, autophagy could contribute to the chondroprotection of PPARα activation by WY14643, with the implication that PPARα activation by WY14643 may be a potential approach for OA therapy.

Citing Articles

Mechanistic and therapeutic insights into the function of N6-methyladenosine in arthritic diseases.

Zhou X, Wu Y, Song Y, Wang B, Cai Y, Miao C Inflamm Res. 2025; 74(1):7.

PMID: 39762508 DOI: 10.1007/s00011-024-01969-3.


PPARδ agonist protects against osteoarthritis by activating AKT/mTOR signaling pathway-mediated autophagy.

Sun G, Li X, Liu P, Wang Y, Yang C, Zhang S Front Pharmacol. 2024; 15:1336282.

PMID: 38576477 PMC: 10991777. DOI: 10.3389/fphar.2024.1336282.


Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms.

Wei G, Lu K, Umar M, Zhu Z, Lu W, Speakman J Bone Res. 2023; 11(1):63.

PMID: 38052778 PMC: 10698167. DOI: 10.1038/s41413-023-00301-9.


Impaired autophagy contributes to the aggravated deterioration of osteoarthritis articular cartilage by peroxisome proliferator-activated receptor α deficiency, associated with decreased ERK and Akt activation.

Zhou Y, Li L, Chen X, Zhao Q, Qu N, Zhang B Eur J Med Res. 2023; 28(1):332.

PMID: 37689723 PMC: 10492277. DOI: 10.1186/s40001-023-01267-4.


Osteoarthritis: Role of Peroxisome Proliferator-Activated Receptors.

Sheng W, Wang Q, Qin H, Cao S, Wei Y, Weng J Int J Mol Sci. 2023; 24(17).

PMID: 37685944 PMC: 10487662. DOI: 10.3390/ijms241713137.


References
1.
Poleni P, Bianchi A, Etienne S, Koufany M, Sebillaud S, Netter P . Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes. Osteoarthritis Cartilage. 2006; 15(5):493-505. DOI: 10.1016/j.joca.2006.10.009. View

2.
Kamekura S, Hoshi K, Shimoaka T, Chung U, Chikuda H, Yamada T . Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage. 2005; 13(7):632-41. DOI: 10.1016/j.joca.2005.03.004. View

3.
Bulhak A, Jung C, Ostenson C, Lundberg J, Sjoquist P, Pernow J . PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol. 2009; 296(3):H719-27. DOI: 10.1152/ajpheart.00394.2008. View

4.
Wagner J, Shadoan M, Zhang L, Ward G, Royer L, Kavanagh K . A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J Pharmacol Exp Ther. 2010; 333(3):844-53. DOI: 10.1124/jpet.110.166736. View

5.
Roughley P, Mort J . The role of aggrecan in normal and osteoarthritic cartilage. J Exp Orthop. 2016; 1(1):8. PMC: 4648834. DOI: 10.1186/s40634-014-0008-7. View